Is Glasdegib on the market?

Glasdegib also known asPF-04449913, is a small molecule inhibitor of the Hedgehog signaling pathway and belongs to the benzimidazole class of compounds. Due to their excellent physicochemical properties and pharmacokinetic properties, this class of compounds attracted widespread attention in early research. Glasgib effectively inhibits the abnormal activation of the Hedgehog signaling pathway by targeting the sonic hedgehog receptor Smoothened (SMO) in cancer cells. This mechanism plays an important role in the pathophysiology of acute myeloid leukemia (AML).

Glasgib was approved by the U.S. Food and Drug Administration (FDA) in November 2018 for the treatment of acute myeloid leukemia. Subsequently, in June 2020, the drug was also approved by the European Medicines Agency (EMA) in the EU under the trade name Daurismo. Clinical studies have shown that the combination of Glasgib and low-dose cytarabine can significantly extend the survival of patients with poor prognosis who are often unable to receive standard chemotherapy due to age or other health factors, so this treatment option provides new hope for them.

In clinical application, Glasgib has been shown to be well tolerated and its side effects are considered controllable. This makes it a viable option for treating patients with acute myeloid leukemia, especially those for whom traditional treatments are not suitable. Due to the role of the Hedgehog signaling pathway in a variety of cancers, Glassgibb's research is not limited to AML and may be expanded into the treatment of other types of tumors in the future.

In summary, Glasgib, as an emerging anti-cancer drug, has been approved in many countries and has proven its effectiveness and safety in clinical practice. With in-depth research on its mechanism of action, the drug is expected to play a greater role in the field of cancer treatment and help more patients improve their prognosis.

Reference materials:https://en.wikipedia.org/wiki/Glasdegib